Who we work with

We know the Microbiome is important to our clients, which include

Testimonials

SeqBiome provides excellent technical and scientific services from sample processing to the analysis of sequencing data. The whole team is very professional, reliable and supportive and we enjoy the fast (and always friendly) communication. We are pleased to have SeqBiome as a partner for high quality microbiome analysis and are looking forward to continue our excellent collaboration.

Weleda AG

Very friendly, reliable and supportive team to interact with. I’m 100% satisfied with their service

AO Research Institute Davos

The SeqBiome team were wonderful in setting up and transferring a customised bioinformatic pipeline to my team that has saved us months of project time

Prof Liam O’Mahony, UCC

It was a pleasure to work with the SeqBiome team, and their flexibility and broad technical knowledge was a huge benefit for us in designing a workplan which was tailored to our exact needs. We are confident that we have a reliable, high-quality report suitable for review by regulatory authorities and partners

PrecisionBiotics Global

We engaged Seqbiome because they could provide tailor made solutions for microbiome sequence analysis that could advance our knowledge on potential bacterial strain application. Seqbiome delivered on their promise to offer us a high quality interactive service with clear interpretable data reporting for immediate business application. We look forward to a continuous partnership with Seqbiome

H&H Group

The demand for high-quality microbiome analysis from our clients has increased dramatically in recent years. We are excited to have formed a strategic partnership with SeqBiome who complement our services in a significant way. The SeqBiome team are recognised across the globe as some of the most experienced scientists in their field. We are very much looking forward to working and scaling with them in this fast growing market.

Atlantia Clinical Food Trials

News & Insights - Highlights

Our partner Freya Biosciences announces positive microbiome therapy for vaginal dysbiosis

June 26, 2023

We are delighted to have contributed to the positive outcomes from the Freya Bioscience’s first Phase 1 clinical study of its lead asset FB101, which is an investigational immunotherapeutic targeting vaginal microbial dysbiosis. Together also with Atlantia Clinical Trials, we evaluated the longitudinal change in the vaginal microbiome after vaginal administration of FB101 in women with asymptomatic vaginal tract dysbiosis, and found that FB101 let to a rapid and sustained switch from a dysbiotic to a Lactobacillus-dominated microbiome. Half of the women showed that engraftment of the Lactobacilli species was established, as determined by strain-level engraftment analysis. Freya intends to expand studies of FB101 for improving fertility outcomes and enhancing the success rates of IVF.

Mapping gut microbiome transfer from mother to baby

June 12, 2023

Our CTO is the last author in a recently published study in Nature Communications, the most in-depth investigation to date of mother-to-infant transmission of common gut bacteria. The project that is titled MicrobeMum shows that the transfer of gut bacteria from a mother to an infant is a common phenomenon, which is strongly influenced by external factors including mode of delivery and exposure to antibiotics in labour. The findings could support the development of targeted probiotic supplements based on these bacteria, with potential benefits to boost immune systems, increase microbial infection resistance, fight disease and even aid digestion.

SeqBiome sponsors conference on microbiome bioinformatics and machine learning

June 10, 2023

SeqBiome is proud to have sponsored a conference on the next-generation bioinformatics tools for microbiome research hosted at the beautiful Aula Maxima at University College Cork. It was hosted jointly by one of the world’s largest microbiome institutes APC Microbiome Ireland and the COST Action ML4Microbiome, which is led by CEO Marcus Claesson and has 170 members across 35 countries. The aim of this 4-year Action is to optimise, standardise and disseminate best practice of Machine Learning for analysing human microbiome data.

In addition to progressing this highly cross-disciplinary field and network, ML4Microbiome has trained a large number of young researchers in these sciences, whereas others have obtained means to carry out guest research projects across European labs.